142 related articles for article (PubMed ID: 15548719)
1. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.
Zeigler-Johnson C; Friebel T; Walker AH; Wang Y; Spangler E; Panossian S; Patacsil M; Aplenc R; Wein AJ; Malkowicz SB; Rebbeck TR
Cancer Res; 2004 Nov; 64(22):8461-7. PubMed ID: 15548719
[TBL] [Abstract][Full Text] [Related]
2. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Han JH; Lee YS; Kim HJ; Lee SY; Myung SC
Asian J Androl; 2015; 17(2):285-91. PubMed ID: 25337833
[TBL] [Abstract][Full Text] [Related]
3. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
Plummer SJ; Conti DV; Paris PL; Curran AP; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):928-32. PubMed ID: 14504207
[TBL] [Abstract][Full Text] [Related]
4. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450.
Domanski TL; Finta C; Halpert JR; Zaphiropoulos PG
Mol Pharmacol; 2001 Feb; 59(2):386-92. PubMed ID: 11160876
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
[TBL] [Abstract][Full Text] [Related]
6. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
[TBL] [Abstract][Full Text] [Related]
7. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Rebbeck TR; Jaffe JM; Walker AH; Wein AJ; Malkowicz SB
J Natl Cancer Inst; 1998 Aug; 90(16):1225-9. PubMed ID: 9719084
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
Leskelä S; Honrado E; Montero-Conde C; Landa I; Cascón A; Letón R; Talavera P; Cózar JM; Concha A; Robledo M; Rodríguez-Antona C
Endocr Relat Cancer; 2007 Sep; 14(3):645-54. PubMed ID: 17914095
[TBL] [Abstract][Full Text] [Related]
9. CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.
Stone A; Ratnasinghe LD; Emerson GL; Modali R; Lehman T; Runnells G; Carroll A; Carter W; Barnhart S; Rasheed AA; Greene G; Johnson DE; Ambrosone CB; Kadlubar FF; Lang NP
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1257-61. PubMed ID: 15894682
[TBL] [Abstract][Full Text] [Related]
10. Genetic association in
Bellah SF; Salam MA; Billah SMS; Karim MR
Ann Hum Biol; 2023 Feb; 50(1):63-74. PubMed ID: 36688864
[TBL] [Abstract][Full Text] [Related]
11. Intergenic mRNA molecules resulting from trans-splicing.
Finta C; Zaphiropoulos PG
J Biol Chem; 2002 Feb; 277(8):5882-90. PubMed ID: 11726664
[TBL] [Abstract][Full Text] [Related]
12. Decision tree-based modeling of androgen pathway genes and prostate cancer risk.
Barnholtz-Sloan JS; Guan X; Zeigler-Johnson C; Meropol NJ; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1146-55. PubMed ID: 21493872
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the influence of polymorphic variants CYP1A1 2B, CYP1B1 2, CYP3A4 1B, GSTM1 0, and GSTT1 0 in prostate cancer.
Rodrigues IS; Kuasne H; Losi-Guembarovski R; Fuganti PE; Gregório EP; Kishima MO; Ito K; de Freitas Rodrigues MA; de Syllos Cólus IM
Urol Oncol; 2011; 29(6):654-63. PubMed ID: 20884258
[TBL] [Abstract][Full Text] [Related]
14. The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population.
Nogal A; Coelho A; Catarino R; Morais A; Lobo F; Medeiros R
Cancer Genet Cytogenet; 2007 Sep; 177(2):149-52. PubMed ID: 17854673
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
16. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA; McLeod HL; Marsh S
BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
[TBL] [Abstract][Full Text] [Related]
17. Genotype relationships in the CYP3A locus in Caucasians.
Dally H; Bartsch H; Jäger B; Edler L; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Kayser K; Schulz V; Risch A
Cancer Lett; 2004 Apr; 207(1):95-9. PubMed ID: 15050738
[TBL] [Abstract][Full Text] [Related]
18. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.
Krusekopf S; Roots I; Kleeberg U
Eur J Pharmacol; 2003 Apr; 466(1-2):7-12. PubMed ID: 12679136
[TBL] [Abstract][Full Text] [Related]
19. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene.
Gellner K; Eiselt R; Hustert E; Arnold H; Koch I; Haberl M; Deglmann CJ; Burk O; Buntefuss D; Escher S; Bishop C; Koebe HG; Brinkmann U; Klenk HP; Kleine K; Meyer UA; Wojnowski L
Pharmacogenetics; 2001 Mar; 11(2):111-21. PubMed ID: 11266076
[TBL] [Abstract][Full Text] [Related]
20. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Gervasini G; García-Martín E; Ladero JM; Pizarro R; Sastre J; Martínez C; García M; Diaz-Rubio M; Agúndez JA
BMC Cancer; 2007 Jul; 7():118. PubMed ID: 17605821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
